英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：


请选择你想看的字典辞典：
单词字典翻译
defected查看　defected　在百度字典中的解释百度英翻中〔查看〕
defected查看　defected　在Google字典中的解释Google英翻中〔查看〕
defected查看　defected　在Yahoo字典中的解释Yahoo英翻中〔查看〕

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • Immune Checkpoint Inhibitors - NCI - National Cancer Institute
    Immune checkpoint inhibitors are a type of immunotherapy that block immune checkpoint proteins from binding with partner proteins Learn about the cancers treated with checkpoint inhibitors and the side effects they may cause
  • Immune Checkpoint Inhibitors and Their Side Effects
    Immune checkpoint inhibitors, like PD-1 or PD-L1 inhibitors, are treatments that help the immune system recognize and attack cancer cells Learn more here
  • PD-1 and PD-L1 inhibitors - Wikipedia
    The concept of blocking PD-1 and PD-L1 for the treatment of cancer was first published in 2001 [6] Pharmaceutical companies began attempting to develop drugs to block these molecules, and the first clinical trial was launched in 2006, evaluating nivolumab As of 2017, more than 500 clinical trials involving PD-1 and PD-L1 inhibitors have been conducted in more than 20,000 patients [7] By the
  • PD-1 and PD-L1: architects of immune symphony and . . . - Frontiers
    Recent advancements in the combination of immunotherapy with chemotherapy, radiation, and surgical procedures to enhance patient outcomes have also been highlighted Overall, this study offers an in-depth overview of the significance of PD-1 PD-L1 in cancer immunotherapy and its future implications in oncology
  • Programmed death ligand 1 signals in cancer cells - Nature
    Gong, J , Chehrazi-Raffle, A , Reddi, S Salgia, R Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future
  • PD-L1, PD1,TMB and Lung Cancer | American Lung Association
    PD-L1 and TMB are biomarkers that may help provide information about whether or not a patient would benefit from immunotherapy to treat their lung cancer
  • PD-L1: From cancer immunotherapy to therapeutic implications . . .
    The PD-L1 PD-1 signaling pathway is the gold standard for cancer immunotherapy Therapeutic antibodies targeting PD-1, such as nivolumab (Opdivo) and pembrolizumab (Keytruda), and PD-L1, including atezolizumab (Tecentriq), durvalumab (Imfinzi), and avelumab (Bavencio) have received Food and Drug Administration approval and are currently being used to treat various cancers Traditionally, PD-L1
  • PD1 and Immunotherapy: What You Need to Know | Dana-Farber
    Some of the most effective immunotherapy agents for cancer are drugs known as checkpoint inhibitors, which, by blocking PD-1, PD-L1 and related proteins, give the immune system a go-ahead to attack tumor cells Dana-Farber scientist Gordon Freeman, PhD, and his colleagues played a major role in the development of some of these inhibitors
  • Targeting PD-1 PD-L1 interactions for cancer immunotherapy
    Two articles that recently appeared in the New England Journal of Medicine 1,2 highlight the therapeutic potential of agents that target PD-1 or its ligand PD-L1 in patients with advanced cancer, even individuals with lung or brain metastases If confirmed, this clinical breakthrough will open novel avenues for cancer immunotherapy





中文字典-英文字典  2005-2009